A share price of Neurogene Inc [NGNE] is currently trading at $19.19, up 28.36%. An important factor to consider is whether the stock is rising or falling in short-term value. The NGNE shares have gain 11.57% over the last week, with a monthly amount glided 12.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neurogene Inc [NASDAQ: NGNE] stock has seen the most recent analyst activity on June 17, 2025, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $50. Previously, Robert W. Baird downgraded its rating to Neutral on May 16, 2025, and kept the price target unchanged to $24. On June 27, 2024, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $65 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $54 on June 11, 2024. Leerink Partners initiated its recommendation with a Outperform and recommended $46 as its price target on April 29, 2024. William Blair started tracking with a Outperform rating for this stock on March 21, 2024, and assigned it a price target of $61. In a note dated January 08, 2024, H.C. Wainwright initiated an Buy rating and provided a target price of $45 on this stock.
Neurogene Inc experienced fluctuations in its stock price throughout the past year between $6.88 and $74.49. Currently, Wall Street analysts expect the stock to reach $34.67 within the next 12 months. Neurogene Inc [NASDAQ: NGNE] shares were valued at $19.19 at the most recent close of the market. An investor can expect a potential return of 80.67% based on the average NGNE price forecast.
Analyzing the NGNE fundamentals
Gross Profit Margin for this corporation currently stands at -16.02% with Operating Profit Margin at -97.02%, Pretax Profit Margin comes in at -87.43%, and Net Profit Margin reading is -87.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.36 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.50 points at the first support level, and at 11.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.04, and for the 2nd resistance point, it is at 24.88.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Neurogene Inc [NASDAQ:NGNE] is 21.03. On the other hand, the Quick Ratio is 21.03, and the Cash Ratio is 5.02. Considering the valuation of this stock, the price to sales ratio is 294.29, the price to book ratio is 0.98.
Transactions by insiders
Recent insider trading involved Cobb Stuart, Chief Scientific Officer, that happened on May 14 ’25 when 6797.0 shares were sold. Officer, STUART COBB completed a deal on May 14 ’25 to buy 6797.0 shares. Meanwhile, President and CFO Cvijic Christine Mikail sold 4501.0 shares on Mar 13 ’25.
